Key Players
Competitive Landscape
Competition in mild cognitive impairment nutrition runs across four business models with sharply different evidence burdens and channel routes. Medical-nutrition groups and cognitive-ingredient developers operate alongside supplement brands and regional functional-food companies. Medical-nutrition groups compete nearest clinical assessment, but consumer brands face greater exposure to public claims enforcement. Ingredient developers gain influence as evidence transfers into multiple finished formats without extending beyond the tested cognitive outcome.
Commercial activity shifted toward product-specific memory propositions during 2025 as companies sought clearer routes into repeat consumer use. Kirin Holdings announced Aodama Premium Immunity, Sleep and Memory for Japan in August 2025 under the Foods with Function Claims route. Quincy Bioscience became the official brain supplement partner of USA Ski & Snowboard in October 2025. Companies now compete on evidence depth, daily usability and channel-ready claim language more directly than broad brain-health branding.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In September 2025, Cadila Pharmaceuticals launched Nu Nutridac for neurodegenerative and anxiety-related nutrition support. | Clinicians and consumers seek nutrient formats that fit neurological care discussions. | Nutrition propositions are moving closer to defined cognitive or neurological use contexts. | Brands can earn revenue from professionally discussed daily capsules with carefully bounded claims. |
| In September 2025, Thorne launched a national creatine campaign that included cognition among documented benefit areas. | Consumers increasingly evaluate ingredients across physical and cognitive performance needs. | Multi-benefit nutrients are broadening the competitive field around cognitive-support supplementation. | Cross-category education can support repeat purchasing among older and performance-oriented consumers. |
| In February 2025, SFI Health launched Equazen in Portugal with local pharmacy and parapharmacy distribution. | Regional access depends on trusted retail channels for researched omega-fatty-acid products. | Cognition-focused nutrition companies are extending established formulas through local distribution partnerships. | Pharmacy-led market entry offers a route to professional visibility and repeat replenishment. |
Other relevant competitors include dsm-firmenich, Pharmavite and Nordic Naturals across cognitive ingredients, omega-3 formats and consumer memory-support products.
Source: Future Market Insights, Mild Cognitive Impairment Nutrition and Cognitive Health Supplement Market Reports, 2026-2036.
Leading companies collectively cover supervised medical nutrition and researched cognitive ingredients alongside pharmacy-access supplements and direct consumer memory products.
Who leads the mild cognitive impairment nutrition market?
Danone Nutricia and Nestle Health Science hold the strongest documented MCI-specific medical-nutrition positions among the profiled companies.
Which suppliers have documented qualification or quality approvals?
Thorne documents NSF Certified for Sport status on its creatine platform, although national food and supplement rules still govern market access.
Which companies provide cognitive-support nutrition products?
Reckitt, Kirin Holdings, Quincy Bioscience, SFI Health and dsm-firmenich market products or programs positioned around memory or cognitive support.
Which suppliers serve North America and Europe?
Nestle Health Science documents North American research investment, whereas SFI Health extended Equazen through Portuguese pharmacy channels in February 2025.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| dsm-firmenich | Global nutrition-ingredient group expanding medical-nutrition options for age-related cognitive decline. | In October 2025, expanded its medical-nutrition offering for age-related decline with broader ingredients and intake options. |
| Aker BioMarine | Global marine-ingredient developer with a brain-health platform centered on Lysoveta. | In January 2026, joined the Innovation Center for Neuroresilience as an industry partner in nutrition-focused neurodegenerative-disease research. |
| Quincy Bioscience | USA consumer memory-supplement company operating under heightened claims scrutiny. | In October 2025, became the official brain supplement partner of USA Ski & Snowboard. |
| Cadila Pharmaceuticals | India-based pharmaceutical manufacturer at the edge of scope through nutritional support around neurological conditions. | In September 2025, launched Nu Nutridac capsules for neurodegenerative and anxiety-related nutritional support. |
| Thorne | USA science-led supplement company with practitioner and direct-consumer distribution. | In September 2025, launched a national creatine campaign that included cognition among supported use areas. |
| Kirin Holdings | Japan-based health-science group commercializing functional foods and cognitive ingredients across Asia-Pacific. | In August 2025, announced the Japan launch of Aodama Premium Immunity, Sleep and Memory. |
| SFI Health | Natural-health company with cognition-focused omega-fatty-acid brands and regional distribution partners. | In February 2025, launched Equazen in Portugal through Eqyon Healthcare Solutions. |
| Nestle Health Science | Global medical-nutrition company with an active mild cognitive impairment program. The cited action covers broader healthy-aging nutrition research. | In October 2025, formed a partnership with the University of California, Davis Innovation Institute for Food & Health to advance nutrition and health-science research. |
Research Methodology
The companies mapped here illustrate market structure without forming an exhaustive ranking. Inclusion requires current verifiable evidence that a company supplies nutrition products or ingredients positioned for mild cognitive impairment, memory support or closely defined cognitive function within the stated market boundary. Evidence comes from regulatory approvals, third-party certifications, company announcements, product documentation, and public filings. Capabilities are attributed to the stated cognitive-nutrition platform or product family instead of broader corporate portfolios. Market-share estimates remain proprietary FMI assessments for the forecast period.
